Pharvaris N.V. (PHVS) company profile
Close on Nov 12, 2026Market cap $2.21BP/E –Yield –
About Pharvaris
Pharmaceutical Preparations, SIC 2834
Pharvaris N.V. is a clinical-stage biopharmaceutical enterprise focused on discovering and advancing novel oral therapies. The company is developing treatments targeting bradykinin-mediated conditions, specifically focusing on hereditary angioedema. Its main developmental product candidates are oral formulations of deucrictibant, which include immediate-release capsules designed for acute attack management and extended-release tablets intended for preventative treatment. Its target customer base consists of individuals suffering from rare angioedema disorders and related conditions.
The company coordinates clinical development internationally, conducting clinical trials across North America and Europe. It supports these initiatives through legal entities and operations located in the Netherlands, Switzerland, and the United States. Pharvaris N.V. maintains its principal executive headquarters in Leiden, the Netherlands.
Summary of the business section of Pharvaris's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pharvaris N.V.
- Headquarters
- Leiden, Netherlands
- Address
- J.H. Oortweg 21, 2333 Ch Leiden
- Phone
- 31 (0)71 203 6410
- Website
- pharvaris.com
- Employees
- 80,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- P7
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers Accountants N.V, Amsterdam, The Netherlands
Stock & identifiers
- Ticker
- PHVS
- Exchange
- Nasdaq
- IPO date
- Feb 8, 2021
- Shares outstanding
- 65M, Dec 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1830487
- CUSIP
- N69605108
- FIGI
- BBG00YYCW1N8
- Share class FIGI
- BBG00YYCW2H3
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Berndt Modig | Chief Executive Officer, Director | 778,334 |
| Peng Lu | President | 110,035 |
| David W. Nassif | CFO / CLO | 114,300 |
| Anne Lesage | Chief Early Development | 130,419 |
| Stefan Andreas Abele | Chief Technical Ops Officer | 40,468 |
| Wim Souverijns | Chief Commercial Officer | 39,021 |
| Anna Nijdam | Principal Accounting Officer | 46,275 |
| Annick Deschoolmeester | Chief Human Resources Officer | 92,553 |
| Viviane Monges | Director | 17,469 |
| Johannes Gerardus Christiaan Petrus Schikan | Director | 115,167 |
| Robert Glassman | Director | 10,500 |
| Elisabeth Bjork | Director | 15,167 |
| David P. Meeker | Director | 65,167 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 8, 2021
- Offer price
- $20.00
- Exchange
- Nasdaq
- First trading day
- Feb 5, 2021
- First-day close
- $29.00+45.0%
- Lock-up ends (est.)
- Aug 4, 2021
“The initial public offering price is $20.00 per ordinary share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“According to HAE International, as of October 2014, HAE affected from 1:30,000 to 1:80,000 individuals globally, or at least 7,000 patients in the U.S.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 8, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 4, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Feb 4, 2021 | Name change | Name changed from Pharvaris, B.V. to Pharvaris N.V. |
See a number that looks wrong?